Bridge Therapeutics

Bridge Therapeutics is a private, pre-revenue biotech founded in 2019, targeting the dual crises of chronic pain and opioid addiction. The company's strategy centers on two clinical-stage assets: BT-219, designed to improve the delivery of the established OUD treatment buprenorphine-naloxone, and BT-205, a combination therapy intended to allow chronic pain patients to transition off standard opioids without withdrawal or euphoria. Operating as a virtual or lean organization, Bridge is pursuing FDA approval for both programs, aiming to address significant unmet needs in a large and challenging market. The company's mission is to 'separate pain from addiction' by providing therapies that manage pain effectively while minimizing abuse potential.

Focused on improved drug delivery systems and patented combination pharmacology for known compounds, specifically targeting abuse-deterrence and improved patient experience in opioid therapy.

In OUD, BT-219 competes with numerous approved buprenorphine formulations (Suboxone, Sublocade, Probuphine) and other MOUDs. In chronic pain, BT-205 would compete against other abuse-deterrent opioids, non-opioid analgesics, and novel mechanisms. Differentiation hinges on proving superior delivery (BT-219) or a unique analgesic without euphoria (BT-205).